Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lonza Inks Biologic Manufacturing Pacts

by Rick Mullin
March 28, 2011 | A version of this story appeared in Volume 89, Issue 13

[+]Enlarge
Credit: Lonza
Lonza will manufacture Enobia’s drug at its Portsmouth, N.H., site.
Credit: Lonza
Lonza will manufacture Enobia’s drug at its Portsmouth, N.H., site.

Lonza has signed a drug development and manufacturing agreement with Athera Biotechnologies, part of Sweden’s Karolinska Development. Under the agreement, the Swiss contract services company will initiate cell-line and process development for Athera’s monoclonal antibody, PC-mAb, intended for the treatment of patients with acute coronary syndrome. Lonza has also signed an agreement with Enobia for the development of the Montreal firm’s enzyme replacement therapy ENG-0040, which has completed Phase II trials for juvenile rickets.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.